Modulation of A₁ and A₂B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy

S Daniele¹², E Zappelli¹², L Natali¹, C Martini*¹ and ML Trincavelli¹

Therapies that target the signal transduction and biological characteristics of cancer stem cells (CSCs) are innovative strategies that are used in combination with conventional chemotherapy and radiotherapy to effectively reduce the recurrence and significantly improve the treatment of glioblastoma multiforme (GBM). The two main strategies that are currently being exploited to eradicate CSCs are (a) chemotherapeutic regimens that specifically drive CSCs toward cell death and (b) those that promote the differentiation of CSCs, thereby depleting the tumour reservoir. Extracellular purines, particularly adenosine triphosphate, have been implicated in the regulation of CSC formation, but currently, no data on the role of adenosine and its receptors in the biological processes of CSCs are available. In this study, we investigated the role of adenosine receptor (AR) subtypes in the survival and differentiation of CSCs isolated from human GBM cells. Stimulation of A₁AR and A₂BAR had a prominent anti-proliferative/pro-apoptotic effect on the CSCs. Notably, an A₁AR agonist also promoted the differentiation of CSCs toward a glial phenotype. The differential effects of the two AR agonists on the survival and/or differentiation of CSCs may be ascribed to their distinct regulation of the kinetics of ERK/AKT phosphorylation and the expression of hypoxia-inducible factors. Most importantly, the AR agonists sensitised CSCs to the genotoxic activity of temozolomide (TMZ) and prolonged its effects, most likely through different mechanisms. are as follows: (i) by A₂BAR potentiating the pro-apoptotic effects of TMZ and (ii) by A₁AR driving cells toward a differentiated phenotype that is more sensitive to TMZ. Taken together, the results of this study suggested that the purinergic system is a novel target for a stem cell-oriented therapy that could reduce the recurrence of GBM and improve the survival rate of GBM patients.

Cell Death and Disease (2014) 5, e1539; doi:10.1038/cddis.2014.487; published online 27 November 2014

Glioblastoma multiforme (GBM), classified as grade IV on the World Health Organization scale,¹ is the most common type of primary malignant brain tumour.² The current therapeutic strategy includes surgery followed by radiation and chemotherapy using temozolomide (TMZ). This therapeutic approach slightly improves the survival rate of GBM patients, but their prognosis remains poor and most patients die of tumour recurrence.³ The causes of the recurrence of GBM are complex and include the high proliferative index of the tumour cells and their resistance to chemotherapy and radiotherapy, particularly in the case of the cancer stem cells (CSCs). These cells have been proposed to not only initiate the genesis of GBM and contribute to its highly proliferative nature, but to also be the basis for its recurrences following treatment. Moreover, it has been reported that the most aggressive or refractory cancers contain the highest number of CSCs.⁴–⁶

These findings suggest that innovative stem cell-oriented therapy may be an effective strategy to reduce tumour recurrence and significantly improve GBM treatment outcomes.⁷–¹⁸ This type of therapy may not be easy to implement because CSCs have been shown to have a low level of reactive oxygen species¹⁹ and to be more resistant to ionising radiation,²⁰ vincristine,²¹ hypoxia and other chemotherapeutics²² compared with non-CSCs. In contrast, the preferential elimination of the CSC population may contribute to the effectiveness of TMZ, which is the most effective pharmacologic agent used in glioma treatment;²³ however, the activity of TMZ appears to be short lived because the drug causes the reversible blockage of the cell cycle of CSCs.²⁴ Moreover, long-term TMZ therapy results in the occurrence of drug-resistant GBM cells,²⁵ indicating the need to develop distinct strategies to overcome this resistance.

Extracellular purines have been implicated in several aspects of GBM biology, such as proliferation,²⁶ migration,²⁷ invasion²⁸ and death.²⁹ The concentration of adenosine in the extracellular fluid of glioma tissue was reported to be in the low micromolar range,³⁰ which is sufficiently high to stimulate all the four of the adenosine receptor (AR) subtypes (A₁, A₂A, A₂B, A₃).³¹ Each of the ARs have a pivotal role in the control of tumour growth and invasiveness³²–³⁴ but to date, no data on their role in CSC biology are available. Recently, it was demonstrated that treatment with adenosine triphosphate reduced the rate of sphere formation by glioma cells and that purinergic receptors are differentially expressed in spheres of tumour cells and adherent cells.³³ In this study, we investigated the role of AR subtypes in the survival and differentiation

¹Department of Pharmacy, University of Pisa, Pisa, Italy
*Corresponding author: C Martini, Department of Pharmacy, University of Pisa, Via Bonanno, 6, Pisa 56126, Italy. Tel: +39 050 2219522-509; Fax: +39 050 2219609; E-mail: claudia.martini@unipi.it
²These authors contributed equally to this work.

Abbreviations: GBM, glioblastoma multiforme; CSCs, cancer stem cells; ARs, adenosine receptors; TMZ, temozolomide

Received 18.6.14; revised 10.10.14; accepted 15.10.14; Edited by R Johnstone

Citation: Cell Death and Disease (2014) 5, e1539; doi:10.1038/cddis.2014.487; published online 27 November 2014
of CSCs. Globally, our data clarified the role of each AR subtype in CSC functionality and suggested that the purinergic system is a novel pharmacological target for the development of new anti-CSC therapies, particularly those aimed at the treatment of GBM recurrences.

Results

Isolation of the tumour stem cell populations. The formation of neurospheres in vitro in U87MG and U343MG cell cultures was induced by using specific neural stem cell (NSC) medium (Supplementary Figure 1A). The spheres obtained using either U87MG and U343MG cells included significantly more CD133/nestin+ cells and a smaller percentage of GFAP+ cells compared with the pool of whole GBM cells (Supplementary Figures 1B, C and D).

Expression and functionality of the ARs in GBM cells and CSCs: The expression profiles of the ARs in the GBM cell lines and in their CSCs were compared. Real-time PCR (Figure 1a) and western blot (Figures 1b and c) analyses revealed that U87MG and U343MG cells expressed all four of the AR subtypes, as previously reported for other glioma cell lines.36,37 The levels of expression of ARs were found to be significantly more CD133/nestin+ cells and a smaller percentage of CSCs: minimal expression of ARs was observed in U87MG or U343MG cells without selection.36,37

The functional responsiveness of the CSC ARs was evaluated using the GTPγS-binding assay.38 As shown in Figure 1d, treatment with CHA and BAY606583 increased the level of GTPγS binding in a concentration-dependent manner, yielding EC50 values of 6.1 ± 0.5 and 1.9 ± 0.2 nM, respectively; these values are comparable to their affinity constant values vis-à-vis A1AR and A2BAR.39,40 In contrast, CGS21680 and Cl-IBMECA had moderate growth-inhibitory effects, with a maximal percentage of CSC growth inhibition of 37.0 ± 3.5 and 37.9 ± 4.2, respectively (Figure 2c). The effects of the A1AR and A2BAR agonists appeared to be completely counteracted by the selective AR antagonists, DPCPX and MRS1754 (Figure 2d).

Effect of AR ligands on CSC proliferation/viability: Incubating U87MG or U343MG cells with the selective AR agonists for 24 or 48 h did not induce any significant change in the cell proliferation rate (Supplementary Figure 2). After 4 days of A1AR, A2BAR or A3AR stimulation, the rate of cell proliferation was enhanced (Supplementary Figures 2A and B), consistent with published data.31

Similar experiments were then performed on CSCs: none of the AR agonists had a significant effect on the growth of the neurospheres after 24 or 48 h of treatment (Figures 2a and b). In contrast, when the neurospheres were treated for 4 or 7 days with each of the AR ligands, a significant decrease in cell proliferation was observed (Figures 2a and b). Cell counting showed that all of the AR ligands significantly reduced the percentage of living cells beginning at 4 days of treatment, with a greater effect evident after 7 days of treatment (Supplementary Figure 3). These data suggested that the reduced rate of CSC proliferation can be ascribed, at least partially, to a reduction in the number of living cells.

As similar results on cellular viability were obtained in CSCs isolated from U87MG and U343MG cell lines, the subsequent experiments were focused only on U343MG-derived CSCs, chosen as representative GBM cell line.

Then, a dose-response study of the AR agonists was performed. CHA and BAY606583 induced a concentration-dependent inhibition of CSC proliferation, with a maximal percentage of CSC growth inhibition of 59.9 ± 1.5 and 63.6 ± 7.2, respectively, and IC50 values of 11.2 ± 1.0 and 3.4 ± 0.39 nM, respectively (Figure 2c), the latter being values that are comparable to the degree of affinity of these ligands for the A1AR or A2BAR.39,40 In contrast, CGS21680 and Cl-IBMECA had moderate growth-inhibitory effects, with a maximal percentage of CSC growth inhibition of 37.0 ± 3.5 and 37.9 ± 4.2, respectively (Figure 2c). The effects of the A1AR and A2BAR agonists appeared to be completely counteracted by the selective AR antagonists, DPCPX and MRS1754 (Figure 2d), indicating that the anti-proliferative effects of CHA and BAY606583 on CSCs are specifically mediated by the activation of A1AR and A2BAR, respectively.

We then investigated whether the reduction in cell proliferation elicited by the AR agonists could be associated with cellular apoptosis. Treating the cells for 4 days with BAY606583 induced a slight but significant early apoptosis (Figure 2e). In contrast, although a reduction in cell proliferation was demonstrated using the MTS assay (Figure 2d), CHA did not induce cellular apoptosis at this point of treatment (Figures 2e and f). After 7 days, both CHA and BAY606583 induced a significant level of phosphatidyserine externalisation, both without (early apoptosis) and with the occurrence of 7-amino-actinomycin 11 binding to DNA (late apoptosis/death) (Figures 2e and f), with a total percentage of cellular apoptosis of 52.0 ± 0.6 and 56.3 ± 2.6, respectively. These data are consistent with the reduction in the percentage of living cells revealed using the Trypan blue exclusion assay (Supplementary Figure 3).

Treatment with CGS21680 and Cl-IBMECA significantly induced early stage of CSC apoptosis, with total percentages of apoptotic cells of 18.8 ± 1.5 and 19.4 ± 1.8, respectively (Supplementary Figure 4), confirming that stimulating A2AR and A3AR had only moderate effects on CSC viability/apoptosis.

Effects of A1AR and A2BAR agonists on the morphology and differentiation of CSCs: As the most promising anti-proliferative effects of the AR agonists were obtained using CHA and BAY606583, the roles of the A1AR and A2BAR subtypes in CSCs were further investigated. The effects of selective A1 or A2AR agonists on CSC morphology were thus evaluated.

After 7 days of treatment, BAY606583 caused a significant reduction in the area occupied by the cells and the number of neurospheres (Figure 3). These effects were observed after 4 days of treatment, although to a lesser extent (Supplementary Figure 5).

When CSCs were incubated with CHA for 4 days, an increase in the number of adherent cells was observed, and the CSCs began to exhibit cellular processes (Supplementary Figure 5). After 7 days of treatment, an almost loss of floating spheres was noticed (Figures 3a and d) and the cells exhibited significant outgrowth of processes. Comparing these data with those obtained in the Annexin V-staining assay suggested that CHA first induced CSC differentiation and, in a later phase, triggered the apoptosis of the differentiated cells.
Figure 1  Expression of ARs in CSCs derived from U87MG and U343MG cells. (a) The total RNA was extracted from whole U87MG cells and U343MG cells and from the respectively derived CSCs. The relative quantification of the AR subtype mRNAs was performed using real-time RT-PCR, as described in the Materials and methods section. The data were expressed as the fold change relative to the level of expression of each AR subtype in GBM cells (each set to 1) and they are the mean values ± S.E.M. of three different experiments. (b and c) Cell lysates were prepared from whole U87MG cells, U343MG cells and the CSCs derived from them. The AR protein levels were evaluated using western blot analysis, using β-actin as the loading control. (b) Representative western blots. (c) Densitometric analysis of the immunoreactive bands performed using the ImageJ program. The data were expressed as the percentage relative to the level of expression in whole GBM cells, and they are the mean values ± S.E.M. of three different experiments. The significance of the differences was evaluated using a one-way ANOVA with the Bonferroni post-test: *P < 0.05, **P < 0.01, ***P < 0.001 versus the levels of expression in whole GBM cells. (d) [35S]GTPγS binding of U343MG-derived CSCs. Membrane aliquots (30 μg) obtained from CSCs were incubated with the indicated selective AR agonists at various concentrations. All of the data were expressed as the percentages of the level of basal [35S]GTPγS binding (set to 100%), and they are the mean values ± S.E.M. of three different experiments, each performed in duplicate.
The receptor specificity of the CHA- and BAY606583-mediated effects was confirmed using the selective antagonists DPCPX and MRS1754 (Supplementary Figure 6).

To further investigate the mechanisms through which CHA and BAY606583 affected CSC morphology, we then assessed the expression of stem cell and differentiation markers in...
CSCs upon their stimulation with these agonists. Real-time PCR (Figure 4a) and western blot analysis (Figures 4b and c) revealed that BAY606583 did not significantly affect the levels of expression of stem cell markers and of the astrocyte marker, suggesting that stimulation of A2BAR did not change the CSC phenotype. In comparative studies, no alteration of the CSC phenotype was observed with either CGS21680 or Cl-IBMECA treatment (Supplementary Figure 7). In contrast, in CHA-treated CSCs, a significant decrease in the expression of the stemness markers (Figure 4) and a significant increase in the expression of GFAP and Olig2 was observed, demonstrating that CHA promoted CSC differentiation toward a glial phenotype.

Next, we assessed whether CHA- or BAY606583-treated cells could resume growing after the removal of the drug. After the BAY606583 challenge and a wash-out period of 7 or 14 days, spheres began to resume proliferation (Figures 3a–c). In contrast, the CHA-treated cells retained their differentiated morphology even after 14 days of drug wash-out, although some floating spheres were observed (Figures 3a–d). These results were confirmed using the MTS assay (Figure 3e).

**Effects of the A1AR and A2BAR agonists on pro-apoptotic/differentiating pathways:** Different signalling pathways have been demonstrated to have a pivotal role in CSC self-renewal, migration and differentiation, including the phosphatidylinositol 3-kinase (PI3K)/AKT and the MAPK/ERK pathways.44,45 Thus, the effects of the A1AR and A2BAR agonists on the levels of total and phosphorylated ERK1/2 and AKT were first investigated. CSC incubation with AR agonists did not alter total ERK or AKT levels (Supplementary Figure 8). Both CHA and BAY606583 induced a modest but significant inhibition of ERK1/2 phosphorylation, which persisted for the 30 min of CSC incubation (Figure 5a). Both ligands also affected the p-AKT level, although with a different kinetic pattern; whereas CHA inhibited AKT phosphorylation for up to 30 min, BAY606583 caused only a transient blockade of AKT phosphorylation (Figure 5b), suggesting that the kinetics of AKT inhibition may explain the different effects of the two AR agonists.

Several studies have demonstrated that hypoxia-inducible factors (HIFs), including HIF-1α and HIF-2α, have potential biological effects on maintaining the stemness of these cells.46–49 Therefore, the modulation of HIF transcriptional activity upon incubation with the A1 or A2BAR agonists was investigated. Neither of ligands altered the HIF-1α level after 4 days of treatment, whereas both of them caused a significant reduction in the HIF-1α level after 7 days of treatment (Figure 5c), consistent with the marked inhibition of CSC proliferation at this time point.50–52

BAY606583 treatment did not affect the level of HIF-2α mRNA at the analysed time points; in contrast, CHA caused a slight but significant reduction in the level of HIF-2α mRNA by 4 days of treatment (Figure 5c), consistent with the reduction in the levels of expression of the stem cell markers caused by its differentiation-promoting effects. Interestingly, 7 days of CHA treatment enhanced the HIF-2α transcriptional activity, indicating that a different HIF-2α-mediated mechanism may be in effect in CHA-differentiated CSCs. We then investigated whether the AR ligands modulated the expression of the apoptosis regulator Bax, a member of Bcl-2 protein family,53 and of the executioner protein caspase-3, responsible for biochemical and morphological hallmarks of apoptosis.54

BAY606583 induced a significant enhancement of the Bax mRNA level starting at 4 days of treatment, with a maximal effect at the 7th day (Figure 5c). In contrast, CHA increased Bax transcriptional activity only after 7 days of treatment (Figure 5d). At this latter time point, both agonists had also induced a significant level of caspase-3 cleavage (Figures 5e and f).

**Combined effect of the A1/A2BAR ligands and TMZ on CSCs:** Considering that TMZ is the most effective pharmacologic agent used in glioma treatment and has partial and reversible effects on CSCs,55,56 the effect of a combined treatment with TMZ and the A1AR or A2BAR ligand on the survival of CSCs was then examined. TMZ alone significantly inhibited CSC proliferation (Figure 6a), as previously demonstrated.54 Treatment for 7 days with TMZ plus CHA or with TMZ plus BAY606583 had a synergetic/additive effect on the reduction of neurosphere growth (Figure 6a), most likely due to a reduction in the level of cell viability (Supplementary Figure 9).

Consistent with these data, when the alkylating agent was applied in combination with CHA or BAY606583, a significant enhancement of the level of late-stage cellular apoptosis was observed (Figures 6b and c).

To further investigate the effects of such combined therapies, a morphological analysis was performed. TMZ alone significantly decreased both the area occupied by and the number of neurospheres present at 7 days (Figure 7). However, after 14 days of drug wash-out, the TMZ-treated cells recovered their normal cell growth, as confirmed by the MTS assay (Figure 7d).
When combined, TMZ and BAY606583 exerted a synergic/additive effect on inhibiting the proliferation of CSCs and significantly decreased the ability of the cells to resume proliferation (Figure 7). Interestingly, in the presence of TMZ, CHA did not induce CSC differentiation but rather had a synergic/additive effect on reducing the rate of cell proliferation.
relative to that of TMZ-treated cells (Figure 7). Moreover, a significant decrease in the ability of the cells to resume growth was noticed (Figures 7a–d).

The effects of the sequential treatment of CSCs with an AR agonist and TMZ were also investigated. A prior challenge with BAY606583 enhanced the chemotherapeutic effect of TMZ (Figure 8): the percentage of reduction of both the area occupied by and the number of CSC-derived neurospheres was significantly higher in the BAY606583–TMZ-treated cells than in the cells treated with TMZ alone (% of reduction of the area occupied by the neurospheres: TMZ alone = 57.3 ± 4.3%; BAY606583–TMZ = 70.2 ± 0.6%; P < 0.001). Moreover, the ability of the BAY606583–TMZ-treated cells to resume growth at 14 days of wash-out was significantly lower than that of TMZ-treated cells (% of reduction of the area occupied by the neurospheres: TMZ alone = 36.1 ± 3.4%; BAY606583–TMZ = 82.6 ± 4.1%; P < 0.001). These data were confirmed by the MTS assay (Figure 8d).

![Graph showing effects of A1AR and A2BAR agonists on the expression of differentiation and stemness markers in CSCs.](image1)

**Figure 4** Effects of A1AR and A2BAR agonists on the expression of differentiation and stemness markers in CSCs. (a) CSCs derived from U87MG or U343MG cells were treated for 7 days with NSC medium containing DMSO (control), 100 nM CHA or 50 nM BAY606583. At the end of treatment periods, the total RNA was extracted, and relative quantification of the mRNAs for the stem cell marker CD133, the astrocyte marker GFAP, and the oligodendrocyte marker Olig2 were performed using RT-PCR, as described in the Materials and methods section. The data were expressed as the fold change versus the levels of the control and they are the mean values ± S.E.M. of three different experiments. (b and c) CSCs from U343MG cells were treated as in a; at the end of treatment periods, cell lysates were subjected to western blot analysis using antibodies specific for the stem cell marker nestin or the glial-cell marker GFAP. (b) Representative western blots. (c) The bar graph shows the results of the quantitative analysis of the western blots, which was performed using the ImageJ program. The data were expressed as the percentage of optical density of the immunoreactive band relative to that of the control, set to 100% and are the mean values ± S.E.M. of three different experiments. The significance of the differences was determined using a one-way ANOVA with the Bonferroni post-test: *P < 0.05, **P < 0.01, ***P < 0.001 versus control.
In a similar way, after CHA-induced CSC differentiation occurred, the effect of TMZ on cell proliferation was significantly stronger (Figures 8a–d). Notably, when TMZ was applied to cells that had been induced to differentiate by CHA treatment, the number of cells per well was decreased and was further decreased after 14 days of drug wash-out.

**Figure 5** Effects of A1AR and A2BAR agonists on pro-apoptotic/differentiating pathways. (a and b) U343MG-derived CSCs were treated for 5 or 30 min with complete medium containing DMSO (control), 100 nM CHA or 50 nM BAY606583. Following the treatments, the levels of ERK 1/2 (a) and AKT (b) phosphorylation were evaluated using ELISA kits, as described in the Materials and methods section. The data were expressed as the percentage of phosphorylated AKT or ERK1/2 relative to those of untreated cells (control), which were set at 100%, and are the mean values ± S.E.M. of three independent experiments performed in triplicate. (c and d) CSCs derived from U343MG cells were treated for 4 or 7 days with NSC medium containing DMSO (control), 100 nM CHA or 50 nM BAY606583. At the end of the treatment periods, the total RNA was extracted, and the relative quantification of the HIFs (c) and Bax (d) mRNAs was performed using RT-PCR. The data were expressed as the fold change versus the level of the control and are the mean values ± S.E.M. of three different experiments. (e and f) CSCs derived from U343MG cells were treated as in a for 7 days. The cell lysates were subjected to western blot analysis using an antibody specific for caspase-3 cleavage products. (e) Representative western blots. (f) The bar graph shows the results of the quantitative analysis of the western blots, which was performed using the ImageJ program. The data were expressed as the percentage of optical density of the immunoreactive band relative to that of the control, set to 100%, and are the mean values ± S.E.M. of two different experiments. The significance of the differences was determined using a one-way ANOVA with the Bonferroni post-test: *P < 0.05, **P < 0.01, ***P < 0.001 versus control.
These results suggested that the CHA-differentiated cells had become sensitive to TMZ and that the effect of the sequential treatments were long lasting.

**Discussion**

In this study, we found that purinergic receptors for adenosine, and particularly the A<sub>1</sub>AR and A<sub>2B</sub>AR subtypes, had a pivotal role in the survival and/or differentiation of glioblastoma CSCs.
Stimulation of either the $A_1$AR and $A_2$BAR had a prominent anti-proliferative effect on the CSCs, and, most importantly, sensitised these cells to the chemotherapeutic activity of TMZ, as follows: (i) by exerting synergic/addictive effects in promoting cell apoptosis and (ii) by almost completely blocking the ability of cells to resume proliferation.
CSCs are responsible for the genesis and recurrence of gliomas and show heightened resistance to irradiation and chemotherapy. CSCs and normal NSCs share core signaling pathways but also display critical distinctions that provide important clues to useful therapeutic targets. In this respect, one therapeutic strategy specifically directed towards the CSC pool consists of forcing these cells to undergo differentiation. For example, glioma CSCs can be strongly driven toward glial or neuronal differentiation by the use of cannabinoid ligands or inductors of cell autophagy.

In addition to differentiating agents, several inhibitors of neurosphere proliferation have been evaluated. Appropriate neurotransmission signalling appears to be required for the maintenance of NSCs, and compounds that affect purinergic receptors, among others, affected the formation of spheres of tumour cells. Therefore, in this study, we focused on the purinergic receptors for adenosine. Each of ARs has indeed a pivotal role in the control of tumour growth and invasiveness but no data on their role in CSC biology are available to date. We showed that in the CSCs derived from GBM cells, selective AR agonists generally reduced the level of cell proliferation/viability after 4–7 days of treatment. The strongest inhibition of cell proliferation was obtained upon stimulation of the A1AR and A2BAR subtypes.

Then, the morphology and stemness/differentiation of CSCs upon treatment with selective AR agonists were evaluated. BAY606583 caused a reduction in the area occupied by and the number of CSC spheres, and induced a significant level of CSC apoptosis beginning at 4 days of treatment. However, the effects elicited by the A2BAR agonist were reversible and not long lasting. In contrast, CHA-treated cells showed the prominent outgrowth of cellular processes, with a significant reduction in the levels of the stemness markers and a concomitant increase in the levels of the glial markers. As the A1AR agonist induced CSC apoptosis after 7 days of treatment but not at the 4th day, we speculated that CHA most likely favours the differentiation of CSCs and the subsequent apoptosis of the differentiated cells. At the same time points, A1AR stimulation did not have a significant effect on the proliferation of GBM cells, suggesting that CHA preferentially depleted the differentiated CSCs rather than GBM cells.

Then, the signalling pathways most likely to be implicated in the CHA- or BAY606583-mediated effects on the proliferation and differentiation of CSCs were investigated. It has been demonstrated that the PI3K/AKT/mTOR signalling pathway is critical for the maintenance of the properties of glioma CSCs and that the dual inhibition of PI3K/AKT/mTOR and MEK/ERK signalling induced the differentiation of and inhibited the tumorigenic potential of CSCs.

Figure 7 Effect of combined treatments with TMZ and A1AR or A2BAR agonists on CSC morphology. (A) CSCs were treated for 7 days with complete NSC medium containing DMSO (a), 100 μM TMZ (b) or TMZ in combination with 100 nM CHA (c), or containing TMZ in combination with 50 nM BAY606583 (d). At the end of treatment periods, the drug-containing media were replaced with fresh drug-free NSC medium, and the cells were cultured for another 7 (a′, b′, c′, d′) or 14 (a″, b″, c″, d″) days. Representative micrographs taken after 7 days of treatment and after 7 or 14 days of drug wash-out are shown A. The area of the culture plates occupied by the spheres (B) and the number of spheres (C) were determined after 7 days of treatment and after 14 days of drug wash-out. The counts are the mean values ± S.E.M. of three independent experiments. The significance of the differences was determined using a one-way ANOVA with the Bonferroni post-test: *P < 0.05, **P < 0.01 versus control. (D) CSCs were treated as in A and their proliferation was evaluated using the MTS assay. The data were expressed as the percentage relative to that of the untreated cells (control), which was set to 100%, and they are the mean values ± S.E.M. of three independent experiments, each performed in duplicate. The significance of the differences was determined using a one-way ANOVA with the Bonferroni post-test: ***P < 0.001 versus control; **P < 0.01 versus TMZ alone. (E) CSCs were treated as in A and their proliferation was evaluated using the MTS assay. The data were expressed as the percentage relative to that of the untreated cells (control), which was set to 100%, and they are the mean values ± S.E.M. of three independent experiments, each performed in duplicate. The significance of the differences was determined using a one-way ANOVA with the Bonferroni post-test: ***P < 0.001 versus control; **P < 0.01 versus cells treated for seven days.
before treating them with TMZ potentiated the anti-proliferative effects of this chemotherapeutic agent, prolonging its effective period. These results strongly suggested that modulating the activity of ARs may be an efficient strategy to sensitize glioma CSCs to chemotherapy and that ARs may be invaluable targets in glioma stem cell-oriented therapies.

Materials and Methods

Materials. N1-cyclo-hexyladenosine (CHA), (±)-3-[6-amino-9-(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydro-oxolin-2-yl]purin-2-yl]amino]phenyl]propanoic acid (CGS21680), 2-chloro-N6-(3-benzodioxol-5-yl)-adenosine-5’-N-methylcarboxamide (Cl-IB-MECA), 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) and TMZ were purchased from Sigma-Aldrich (Milan, Italy). [2-β-Aminos-3,5-dioxano-4-(cyclopropylmethyl)phenyl]pyridin-2-ylsulfanyl]acetic acid (BAY606583) and MRS1754 were purchased from Tocris Bioscience (Bristol, UK); the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was obtained from Promega (Milan, Italy). The RNeasy Mini Kit was purchased from Qiagen (Milan, Italy) and the ProtoScript cDNA Synthesis Kit was obtained from Biolabs, Euroclone (Milan, Italy). All of the other reagents that were used were obtained from commercial sources.

GBM cell line culture and CSC isolation. The U87MG and U343MG cell lines were obtained from the National Institute for Cancer Research of Genoa (Italy) and the Cell Lines Service GmbH (Germany), respectively. The DNA profile of each cell line was monitored. The U87MG and U343MG cells were cultured in RPMI medium and Eagle’s minimum essential medium adjusted to contain a final concentration of 1.5 g/l sodium bicarbonate, respectively, supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 1% non-essential amino acids at 37 °C in 5% CO2. Both cell lines were sub-cultured when the monolayer reached 75 to 85% confluence, at which point the average cell density was 1.5 x 103 viable cells/cm2. To isolate CSCs, approximately 2.0 x 105 cells of each GBM cell line was suspended in 1 ml of a defined serum-free NSC medium containing 20 ng/ml of basic fibroblast growth factor (Sigma-Aldrich), 20 ng/ml of epidermal growth factor (Sigma-Aldrich) and 20 ng/ml or 20 μl of B27 supplement (Life Technologies, Milan, Italy). After 3–4 days of culture, the neurospheres were collected, suspended in NSC medium, dissociated into single cells and plated for the assays. For the long-term treatment of cells, NSC or complete medium containing drugs was replaced every 2–3 days.

Cell proliferation/viability assays of GBM cells and CSCs. The human GBM cells or CSCs were seeded at a density of 3 x 104 cells per well. After 24 h, the culture medium was replaced with fresh stem cell culture medium, and the cells were treated for 1–7 days with the AR agonists CHA (A2AR), CGS21680 (A2AR), BAY606583 (A2AR) and Cl-IB-MECA (A2AR) at different concentrations, and with TMZ, alone or in combination. Following the treatment period, cell proliferation was assessed using an MTS assay, according to manufacturer’s instructions. In some experiments, the effects of the AR antagonists on agonist-mediated effects were evaluated. In particular, the A2AR antagonist CGS21680 (50 nM) and the A2AR antagonist MRS1754 (20 nM) were used. The antagonists were added 10 min before the addition of 100 nM CHA or 50 nM BAY606583, respectively.

For the drug wash-out experiments, neurospheres were treated for 7 days with 100 nM CHA, 50 nM BAY606583, and 100 μM TMZ, alone or in combination. For sequential treatments, the cells were pre-treated with AR agonists for 7 days and then with TMZ for another 7 days. At the end of treatment periods, the drug-containing media were replaced with fresh drug-free NSC medium, and the cells were allowed to grow for another 14 days. Within each experiment, a condition was assayed in triplicate, and each experiment was performed at least three times. The results were calculated by subtracting the mean background values from the values obtained under each test condition and were expressed as the percentages of the control (untreated cells) values.

The effects of the combined treatments on CSC viability were also evaluated using the Trypan blue exclusion assay. U87MG-derived CSCs were treated for 1–7 days with CHA, CGS21680, BAY606583 and Cl-IB-MECA at the indicated concentrations and with TMZ (100 μM), alone or in combination. Following the treatment period, cells were collected and centrifuged at 300 x g for 5 min. The harvested cells were mixed with an equal volume of 0.4% Trypan blue dye, and the blue (dead cells) and white (living cells) in each well were manually counted. The number of live cells for each condition was reported as the percentage of living cells relative to that in the control sample.

[35S]GTPγS-binding assay in CSCs. [35S]GTPγS binding to membranes obtained from CSCs was assayed as previously described, with some modifications.3 Brieﬂy, cell membranes (30 μg) obtained from U343MG-derived CSCs were incubated in the assay buffer (50 mM Tris-HCl, 1 mM EDTA, 1 mM MgCl2, 100 mM NaCl, 1 mM DTT, 0.0005% Tween 20 and 0.5% bovine serum albumin) in the presence of 2 units/ml adenosine deaminase, 1 μM GDP and the AR agonists at different concentrations. Binding was initiated by the addition of 0.2 nM [35S]GTPγS and the incubation was continued for 30 min at 25 °C. The level of nonspecific binding was determined using 10 μM unlabeled GTP-S. The reaction was stopped by rapid filtration and the plates were washed twice using 200 μl of buffer. The levels of radioactivity were measured using liquid scintillation spectrometry.

Western blot analysis. CSCs were treated with DMSO (control), 100 nM CHA or 50 nM BAY606583 for 7 days. At the end of the treatment period, the cells were collected and then were lysed for 60 min at 4 °C using 200 μl of RIPA buffer (9.1 mM NaH2PO4, 1.7 mM Na2HPO4, 150 mM NaCl, pH 7.4, 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS and a protease-inhibitor cocktail). Equal amounts of the cell extracts (40 μg of protein) were diluted in Laemmli sample solution, resolved using SDS-PAGE (8.5%), transferred to PVDF membranes and probed overnight at 4 °C using the following primary antibodies: anti-nestin (sc-20978, Santa Cruz Biotechnology, Heidelberg, Germany; 1:50); anti-GFAP (sc-9065, Santa Cruz Biotechnology; 1:50); anti-A2AR (sc-19223, Santa Cruz Biotechnology; 1:200); anti-A2αAR (sc-13637, Santa Cruz Biotechnology; 1:200); anti-A2AR (sc-28996, Santa Cruz Biotechnology; 1:50); and anti-caspase-3 (sc-7148, Santa Cruz Biotechnology; 1:200). The primary antibodies were detected using the appropriate peroxidase-conjugated secondary antibodies, which were then detected using a chemiluminescent substrate (ECL, Perkin Elmer, Waltham, MA, USA). Densitometric analysis of the immunoreactive bands was performed using ImageJ Software (version 1.41; Bethesda, MD, USA).

Quantification of the occupied area and the cellular processes of neurospheres. CSCs isolated from U343MG cells were plated in NSC medium (day 0) and treated for 7 days with 100 nM CHA, 50 nM BAY606583, and 100 μM TMZ, alone or in combination (until day 7). In some experiments, the CSCs were treated with the indicated AR agonist (until day 7), and subsequently with TMZ for another 7 days (until day 14). At the end of the treatment periods, the drug-containing media were replaced with fresh NSC medium, and the CSCs were allowed to grow for another 7 or 14 days. Photographs of the neurospheres were taken.
taken at days 0, 7, 14 and 21; three different wells were analysed for each condition, 15 images of each well were captured (using a 20× objective lens). The response of the cultures to the various treatments was quantified by measuring the area occupied by neurospheres that had formed, using the ImageJ program. The cellular processes extending from the six to eight differentiating neurospheres per condition in three independent experiments were evaluated. To measure the cellular processes, the average diameter of an individual neurosphere in the vertical and horizontal planes was determined. The number of extensions from the body of the neurospheres was counted, and the ratio of the number of extensions at the average neurosphere diameter was calculated. In addition, the neurite lengths were measured. All of the measurements were performed using the ImageJ Program (http://rsbweb.nih.gov/ij/docs/faqs.html#cite).

RNA extraction and real-time PCR analysis. CSCs were treated with proliferation medium containing DMSO (control), CHA, CGS21680, BAY606583 or Cl-IBMECA at the indicated concentrations or TMZ for 4 or 7 days. At the end of the treatment period, the cells were collected, and total RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. The purity of the RNA samples was evaluated by measuring the absorbance at 260 and 280 nm. cDNA synthesis was performed with 500 ng of RNA using the i-Script cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions. The primers used for RT-PCR were designed to anneal to the intron/exon boundaries to ensure that the amplified products did not include genomic DNA. The RT-PCR reaction mixtures consisted of 25 μl of Fluocycle II SYBR (Euroclone), 1.5 μl of 10 mM forward and reverse primers, 3 μl of cDNA, and 19 μl of H2O. All of the reactions were performed for 40 cycles using the following temperature profile: 98 °C for 30 s (initial denaturation); T °C (see Supplementary Table 1) for 30 s (annealing); and 72 °C for 3 s (extension). β-Actin was used as the housekeeping gene. The levels of mRNA in each sample were normalised against the level of β-actin mRNA, and the relative expression was calculated using the Ct value. The specificity of the assays was determined by both melting curve analysis and gel electrophoresis, and the data were analysed using the standard-curve method. For the quantification of AR expression in CSCs, the data were expressed as the fold change relative to the level of expression of each AR subtype in whole GBM cells.

Annexin V and 7-AAD staining. Dual staining with Annexin V conjugated to fluorescein-isothiocyanate (FITC) and 7-aminoactinomycin (7-AAD) was performed to distinguish the viable, early-stage apoptotic, and necrotic or late-stage apoptotic cells. Annexin V–FITC positive and 7-AAD positive were identified as cells in late-stage apoptosis. Annexin V+/FITC− and 7-AAD− cells) values. The results were calculated by subtracting the mean background value from the values obtained under each test condition: values were normalised to the number of GBM cells in each well and were expressed as the percentages of the control (untreated cells) values.

Statistical analyses. The nonlinear multipurpose curve-fitting program GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA) was used to analyse the data and prepare the graphic presentations. All of the data were expressed as mean values ± S.E.M. The data were analysed using a one-way analysis of variance (ANOVA) with Bonferroni’s corrected t-test for post-hoc pair-wise comparisons. P < 0.05 was considered statistically significant.

Conflict of Interest The authors declare no conflict of interest.

Acknowledgements We thank Dr. Chiara Giacomelli for the cell apoptosis analysis.

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2008. Neuro-Oncology 2012; 14: 1–49.
2. Leper J-M, Rees LA, Smith MA, Warren JL, Heineman EF, Kaplan R et al. Cancer surveillance series (corrected); brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999; 91: 1382–1390.
3. Shen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492–507.
4. Erano A, Ricci-Vitiani L, Zeuner A, Paleini A, Lott F, Sette G et al. Chemotherapy resistance of glioblastoma stem cells. Mol Cancer Ther 2009; 8: 1308–1316.
5. Smalley M, Piggott L, Clarkson R. Breast cancer stem cells: obstacles to therapy. Cancer Lett 2013; 338: 57–62.
6. Van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S et al. High-stem cell frequency in acute myeloid leukemia at diagnosis predicts high residual disease and poor survival. Clin Cancer Res 2005; 11: 6520–6527.
7. Aguado T, Carrazeo A, Julian B, Velasco G, Milman G, Mechoulam R et al. Cannabinoids induce glioma stem-cell-like differentiation and inhibit gliomagenesis. J Biol Chem 2007; 282: 8654–8682.
8. Ahmed N, Salaman VS, Kew Y, Shaffer D, Powell S, Zhang Y et al. HER2-specific T cells target primary glioblastoma glioma cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010; 16: 474–485.
9. Aloy MT, Hadchity E, Bionda C, Diaz-Latoud C, Claude L, Rousson R et al. Protective role of Hsp27 protein against gamma radiation-induced apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells. Int J Radiat Oncol Biol Phys 2008; 70: 543–553.
10. Ataner C. Glioblastoma stem cells. Neoplasia 2008; 55: 369–374.
11. Balayesnova IV, Franco-Gou R, Mathis JM, Lesniak MS. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. J Biochem Biophys Res Commun 2010; 4: 247–258.
12. Bar EE, Chaudhry A, Lin A, Fan X, Schrek K, Matsu W et al. Cytoplasmic-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007; 25: 2524–2533.
13. Charness AJ. Adjuvant or adjuvant-like glioma stem cells–therapeutic obstacle or promising target? DNA Repair 2007; 6: 1391–1394.
14. Cho DY, Lin SZ, Yang WK, Hsu DM, Lin HL, Lee HC et al. The role of cancer stem cells (CD133+/+) in malignant gliomas. Cell Transplant 2011; 20: 121–125.
15. Fan X, Saltford LG, Widegren B. Glioma stem cell: evidence and limitation. Semin Cancer Biol 2007; 17: 214–218.
16. Gajd M, Croux AM, Fortin D, Krocé J, Toricha M, Mai S et al. EGFR receptor inhibitors in the treatment of glioblastoma multiforme: old clinical allies and newly emerging therapeutic concepts. Eur J Pharmacol 2009; 625: 23–30.
17. Hughes SA, Achanta P, Ho AL, Duenas VJ, Quiñones-Hinojosa A. Biological horizons for targeting brain malignancy. Adv Exp Med Biol 2010; 671: 93–104.
18. Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, Ju J et al. Growth of cancer cell lines under stem-cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res 2008; 314: 2110–2122.
19. Dinh M, Cho RW, Lobo NA, Kalysky T, Dorie MJ, Kulp AN et al. Association of reactive oxygen species levels and radiosensitivity in cancer stem cells. Nature 2008; 458: 780–783.
20. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radiosensitivity by preferential activation of the DNA damage response. Nature 2006; 444: 765–769.
21. Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, Yao XH et al. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008; 265: 124–134.
22. Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W et al. Isolation and characterization of cancer stem-like cells in human glioblastoma cell lines. Cancer Lett 2009; 279: 13–21.
23. Beier D, Röhl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008; 68: 5706–5715.
24. Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma stem cells–much more complex than expected. Mol Cancer 2011; 10: 128–138.
25. Happold C, Roth P, Wolk W, Schmidt N, Florea AM, Sligner M et al. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem 2012; 122: 444–455.

26. Morone FB, Jacques-Silva MC, Horn AP, Bernard A, Schwartsmann G, Rodnight R et al. Expression and function of the p2x7 receptor in rat C6 glioma cells. Cancer Lett 2008; 260: 79–87.

27. Wei W, Ryu JK, Choi HB, McLarnon JG. Expression and function of the p2x7 receptor in rat C6 glioma cells. Cancer Lett 2008; 260: 79–87.

28. Gessi S, Sacchetto V, Fogli E, Merighi S, Varani K, Baraldi PG et al. Modulation of matrixproteinases-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochim Pharmacol 2010; 79: 1483–1495.

29. Morrone FB, Horn AP, Stella J, Spiller F, Sarkis JJ, Salbego CG et al. Increased resistance of glioma cell lines to extracellular ATP cytotoxicity. J Neurochem 2005; 71: 135–140.

30. Fredholm BB, Ijzermans AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXVI. Nomenclature and classification of adenosine receptors – an update. Pharmacol Rev 2011; 63: 1–34.

31. Merighi S, Miranda P, Varani K, Gessi S, Leung E, Baraldi PG et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 2003; 100: 31–48.

32. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 2008; 117: 123–140.

33. Leduc PF, Villoire ES, Paulus R, Cruz LA, Flores DG, Lenz G. Extracellular ATP reduces tumor sphere growth and cancer stem cell population in glioblastoma cells. PLoS One 2012; 7: 39–48.

34. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochim Biophys Acta 2011; 1: 1400–1412.

35. Piccitolo SG, Reynolds BA, Randini L, Naro M, Binda E, Brogni G et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiing cells. Nature 2006; 444: 761–765.

36. Castillo CA, León D, Ruiz MA, Abasanz JL, Martín M. Modulation of adenosine A1 and A2A receptors in C6 glioma cells during hypoxia: involvement of endogenous adenosine. J Neurochem 2008; 105: 2315–2329.

37. Castillo CA, Abasanz JL, Fernández M, Martín M. Endogenous expression of adenosine A1, A2A and A3 receptors in U87MG glioma cells. Neurochem Res 2007; 32: 1056–1070.

38. Marteau F, Le Poul E, Communi D, Communi D, Labouret C, Savi P et al. Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol 2003; 64: 104–112.

39. Dhallia AK, Shryock JC, Sreenivas R, Belardinelli L. Pharmacology and therapeutic implications of A1 adenosine receptor ligands. Curr Top Med Chem 2003; 3: 369–385.

40. Ortole G, Martinek M, Agnusdottir R, Lingos H. Gas6 receptor ligands: past, present and future trends. Curr Top Med Chem 2010; 10: 923–940.

41. Luthrin DR, Olson RA, Thompson RD, Sawmill DR, Linden J. Characterization of two affinity states of adenosine A2A receptors with a new radioligand, 2-[(4-amino-3-[125I]iodophenyl)ethylamino]adenosine. Mol Pharmacol 1995; 47: 307–313.

42. Lim MH, Kim HO, Moon HR, Lee SJ, Chun MW, Gao ZG et al. Design, synthesis and binding affinity of 3-Fu analogues of Cl-IB-MECA as adenosine A3 receptor ligands. Bioorg Med Chem Lett 2003; 13: 817–820.

43. Cho DY, Lin SZ, Yang WK, Lee HC, Hsu DM, Lin HL et al. Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant 2013; 22: 731–739.

44. Sunayama J, Matsuoka K, Sato A, Tachibana K, Suzuki K, Narita Y et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010; 28: 1930–1939.

45. Li Z, Bao S, Wu Q, Wang H, Eyer G, Salthornsumette S et al. Hypoxia-inducible factors regulate tumorigenicity of glioma cells in vivo. Cancer Cell 2009; 15: 501–513.

46. Plantet N, Liu SY, Atti ME, Oliver L, Vallette FM, Berger F et al. Influence of oxygen tension on CD133 phenotype in glioma cell cultures. Cancer Lett 2007; 258: 286–290.

47. Gibertson RJ, Rich JH. Making a tumor’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007; 7: 723–726.